A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer

  • STATUS
    Recruiting
  • sponsor
    Alliance
Updated on 23 November 2020
estrogen
breast cancer
HER2
tamoxifen
erbb2
estrogen receptor

Summary

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCl in Postmenopausal Women with Metastatic, Estrogen Receptor Positive, HER2 Negative Breast Cancer

Description

You are being asked to participate in this study because you are a postmenopausal woman with estrogen receptor positive and HER2 negative breast cancer that no longer responds to aromatase inhibitors (anti-estrogen therapy) and has spread in the breast, or to other parts of your body. For patients who receive the usual approach for this cancer, tamoxifen, about 20 out of 100 patients are alive without cancer progression after 1 year of treatment. Estrogen receptor positive means that your cancer is potentially sensitive to anti-estrogen therapy. HER2 negative means that you do not have too many HER2 cells, which can cause breast cancer to grow faster. Postmenopausal women with your type of breast cancer are usually treated with hormonal therapy. The purpose of this study is to compare any good and bad effects of using Z-Endoxifen HCL to using tamoxifen. Z-Endoxifen HCL could shrink your cancer and prevent it from spreading, but it could also cause side effects. This study will allow the researchers to know whether this new approach is better, the same, or worse than the usual approach of using tamoxifen. To be better, the study approach should increase the time to cancer progression by 3 months or more compared to the usual approach. Tamoxifen has been approved by the Food and Drug Administration (FDA) of the United States for the treatment of advanced or metastatic (spread outside of the breast or to other parts of the body) breast cancer. Z-Endoxifen HCl is an investigational or experimental anticancer agent that has not yet been approved by the Food and Drug Administration for breast cancer. Tamoxifen and Z-Endoxifen HCl both work by blocking the effects of estrogen in the breast cancer cells. The study researchers also would like to learn more about fatigue and quality of life. All study participants will be asked to complete a two question questionnaire. It will take less than one minute to complete the questions

Details
Condition Breast Cancer
Clinical Study IdentifierTX143634
SponsorAlliance
Last Modified on23 November 2020

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note